HPV vaccination: the beginning of the end of cervical cancer? - A Review

Memórias do Instituto Oswaldo Cruz

Ana Paula Lepique¹  Tatiana Rabachini¹  Luisa Lina Villa¹ 

[1] ,Instituto Ludwig de Pesquisa sobre o CâncerSão Paulo SP ,Brasil

关键词: human papillomavirus;    anogenital cancers;    prophylactic vaccine;    therapeutic vaccine;    clinical trial;   

DOI  :  10.1590/S0074-02762009000100001

来源: SciELO

【 摘 要 】

Human papillomavirus (HPV) is responsible for all cases of cervical cancer, as well as a great percentage of other anogenital tumors and oropharyngeal tumors. Since the main etiologic factor for these diseases is a virus, prophylactic measures are the best way to reduce the burden caused by the infection and associated disease. This review brings up to date information on the two commercially available prophylactic HPV vaccines against HPV, as well as presenting the ongoing research on HPV peptide, protein and dendritic cell based therapeutic vaccines.

【 授权许可】

CC BY   
 All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License